Patent ID: 9242012
Filing Date: 2016-01-26
CPC Classification: A61K,A61P

Claim Text:
1. A method of treating a subject having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, the method comprising: selecting a subject having progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, and administering an effective amount of a prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) to the subject, wherein the PSMA ADC comprises a human monoclonal antibody to PSMA conjugated to monomethylauristatin norephedrine (MMAE) or monomethylauristatin phenylalanine (MMAF), and wherein the effective amount is sufficient to 1) delay or inhibit progression of the cancer, 2) increase survival of the subject as compared to the median survival of subjects who have not been treated with the PSMA ADC and who have progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy, 3) decrease a circulating level of circulating tumor cells (CTCs) compared to a baseline level, or 4) decrease or stabilize a serum level of PSA compared to a baseline level of PSA.